Analysts' average 12-month price target for Bicara Therapeutics Common Stock is $32.
Get informed when a big investor buys or sells
+ Follow$26.1
3 analysts in the last 4 months
High: $42 | Low: $18
No recommendations in the last 4 months.
As of the most recent data, BCAX shows a target price of $32. Scroll down for historical charts and peer comparison views.
If Bicara Therapeutics Common Stock moved to the average analyst target of $32, shares would be roughly 23.9% higher than $26.1. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Bicara Therapeutics Common Stock's earnings trajectory.
Besides this target price page, Stockcircle has Bicara Therapeutics Common Stock's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $32) with ownership activity and broader fundamentals.
Bicara Therapeutics Common Stock's target price is $32; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.